Drug
Cariprazine clinical trials
Also written Vraylar, RGH-188 and MP-214.
- studies test it
- 53
- open now
- 8
- in phase 3
- 27
- first study started
- 2006
Keep track of what changes. Save the cariprazine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
53 studies that test it; most in 2010 (6)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 6 |
| 2011 | 4 |
| 2012 | 6 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2018 | 5 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 5 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 19
- Phase 3
- 27
- Phase 4
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 41 · Other 12
Forest Laboratories (20) · AbbVie (9) · Tanabe Pharma Corporation (6) · Gedeon Richter Plc. (2) · New York State Psychiatric Institute (2) · Massachusetts General Hospital (1) · Humanis Saglık Anonim Sirketi (1) · Kyle Kampman (1)
Often tested with
Tested in the same studies.
Quetiapine (1) · Lurasidone (1) · Antidepressive Agents (1) · Brexpiprazole (1) · Vortioxetine (1) · Lithium (1)
Studies
Open first, then newest update. How each study uses cariprazine is read from its arms, and is right about nine times in ten.
Testing it · 53
- A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.RecruitingPhase 3AbbVieNCT04777357Written as Cariprazine
- A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With SchizophreniaNot yet recruitingPhase 2/3Bostal Drug Delivery Co., LtdNCT07722728Written as Vraylar® 1.5 mg
- Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in SchizophreniaNot yet recruitingPhase 1New York State Psychiatric InstituteNCT07715253Written as Cariprazine
- RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)RecruitingPhase 4Mayo ClinicNCT07266545Written as Cariprazine (Augmentation Phase)
- Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral CariprazineRecruitingPhase 1/2Mapi Pharma Ltd.NCT07185815Written as Oral Cariprazine 3 mg/day
- Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)RecruitingPhase 4Aalborg University HospitalNCT05913947Written as Cariprazine
- Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With SchizophreniaRecruitingPhase 3Gedeon Richter Plc.NCT03817502Written as Cariprazine
- Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive DisorderNot yet recruitingPhase 4Sultan Qaboos UniversityNCT05933538Written as Cariprazine
- Bioequivalence Study to Compare Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) Versus Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine)CompletedPhase 1Humanis Saglık Anonim SirketiNCT07691190Written as Reagila® Hartkapseln (Hard Capsules) (Cariprazine)
- Dopamine D3 Receptor Occupancy in Bipolar DepressionWithdrawnPhase 4New York State Psychiatric InstituteNCT05060549Written as Cariprazine
- Cariprazine for Comorbid Cocaine and Opioid Use DisorderCompletedPhase 2Kyle KampmanNCT05063201Written as Cariprazine 1.5 MG
- A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs SchizophreniaCompletedPhase 2/3Tanabe Pharma CorporationNCT01626885Written as MP-214
- Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With SchizophreniaCompletedPhase 2Tanabe Pharma CorporationNCT00862992Written as Cariprazine 3 mg
- Long-Term Study of MP-214 in Patients With SchizophreniaCompletedPhase 2/3Tanabe Pharma CorporationNCT01626872Written as MP-214 3mg
- A Pharmacokinetic Study of MP-214 in Patients With SchizophreniaCompletedPhase 2/3Tanabe Pharma CorporationNCT01626859Written as MP-214 3mg
- Safety and Efficacy of MP-214 in Patients With SchizophreniaCompletedPhase 2/3Tanabe Pharma CorporationNCT01625000Written as MP-214 3mg
- A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly SchizophreniaCompletedPhase 2/3Tanabe Pharma CorporationNCT01625897Written as MP-214
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionActive, not recruitingPhase 4Massachusetts General HospitalNCT06433635Written as Cariprazine
- Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaTerminatedPhase 3AbbVieNCT05368558Written as Cariprazine
- Bioequivalence Assessment Between Two Cariprazine Hard Capsule FormulationsCompletedPhase 1Aya Mohammed Abdel Magid Abdel HamidNCT07121868Written as Test Product (Vocarzine)
See all 53 studies that test cariprazine →
As the comparator · 2 — what is tested is compared with cariprazine
- This Study Aims to Compare the Efficacy and Safety of Lumateperone and Cariprazine in Patients With Bipolar I Depression Using Montgomery-Åsberg Depression Rating Scale (MADRS) and Clinical Global Impression Bipolar Severity Scale (CGI-BP-S) and Recording Treatment Emergent Adverse EffectsNot yet recruitingPhase 4Watim Medical & Dental CollegeNCT07676669Written as Cariprazine
- Risperidone vs Cariprazine in Acute ManiaNot yet recruitingPhase 4Pakistan Institute of Medical SciencesNCT07665073Written as Cariprazine
Codes
What other systems call cariprazine · ClinicalTrials.gg INT005356
- MeSH (NLM) C533287cariprazineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) F6RJL8B278CARIPRAZINEConfirmed FDA, NLM, Wikidata
- RxNorm 1667655Confirmed FDA, Wikidata
- Wikidata Q2938837cariprazineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169826CariprazineOne source FDA
- DrugBank DB06016One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C533287 | cariprazine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | F6RJL8B278 | CARIPRAZINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1667655 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2938837 | cariprazine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169826 | Cariprazine | One source FDA |
| DrugBank | DB06016 | — | One source Wikidata |
Also registered as cariprazine hydrochloride (UNII KQD7C255YG · RxNorm 1721073).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.